Electromedical Products International鈥檚 (EPI) wholly-owned subsidiary Pulvinar Neuro has for transcranial stimulation (TCS) research.
The company has been awarded a Phase II SBIR grant worth $3.06m from the National Institute of Mental Health (NIMH), a branch of the NIH, over three years to advance its TCS research as a promising treatment for psychiatric disorders.
Pulvinar Neuro will use the funding for the development of a cloud-enabled TCS device to offer personalised closed-loop brain stimulation for clinical and at-home applications.
The grant also covers financing for the TCS device鈥檚 double-blind, placebo-controlled trial in 30 patients with major depressive disorder.
EPI chief science officer Dr Leah Townsend said: 鈥淭his NIH grant will enable us to take a key step forward in the development of our novel brain stimulation treatment for mental illness.
鈥淲e are grateful to NIMH for supporting our work developing this important, innovative technology.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPulvinar Neuro supports the research community by offering non-invasive brain stimulation research tools.
The company is also focused on the technical development of advanced therapeutics for mental health.
EPI offers non-invasive brain stimulation for psychiatric disorders and pain management.
The company manufactures the Alpha-Stim brand of patented devices, which received approval from the US Food and Drug Administration to treat anxiety and insomnia through cranial electrotherapy stimulation and pain via microcurrent electrical therapy.
